Home / Market News / $TEVA
benzinga Corporate Catalyst Impact 85/100 ● positive

Teva Pharmaceuticals Receives FDA Approval Of WELTRUZA For Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Oct 9, 2026, 11:03 AM UTC · Primary ticker $TEVA

Teva Pharmaceuticals has received FDA approval for WELTRUZA, a long-acting injectable olanzapine for schizophrenia. This approval represents a significant new product launch for Teva, addressing a major unmet need in patient adherence for schizophrenia treatment and potentially boosting the company's revenue and market position.

Teva Pharmaceuticals announced FDA approval for WELTRUZA, an extended-release injectable suspension for schizophrenia. This is a significant development as WELTRUZA offers the proven efficacy of olanzapine in a long-acting subcutaneous injectable form, addressing the critical issue of treatment adherence in schizophrenia patients. This approval is a major positive for Teva, as it introduces a new, innovative product into a large market (2.1 million people in the U.S. diagnosed with schizophrenia). Short-term, this could lead to increased investor confidence and potential stock appreciation for Teva. Long-term, successful commercialization of WELTRUZA could significantly contribute to Teva's 'Pivot to Growth' strategy and revenue. Medincell (MDCL) also benefits as their SteadyTeqâ„¢ copolymer technology is utilized in WELTRUZA.

$TEVA positive FDA approval of new drug
$MDCL positive Proprietary technology utilized in approved drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.